Skip to main content
OpenTrials
Completed

NCT Number: NCT01928953

Longitudinal Study of Patients With Opioid-Induced Constipation

This prospective hybrid longitudinal study was conducted in the United States (US), Canada, the United Kingdom (UK), and Germany. To obtain the most complete and comprehensive understanding of the burden of opioid-induced constipation (OIC) in these countries, this study used a combination of web-based, longitudinal patient survey, retrospective data abstraction from medical records, and a prospective physician survey.

The primary objective of this study was to estimate the rate of inadequate response to laxatives (LIR), which was defined as having sufficient laxative use (at least one laxative use ≥ four times per reference period), and inadequate response (defined as fewer than three bowel movements (BMs) OR at least one of the following symptoms on the Patient Assessment of Constipation Symptoms (PAC-SYM) measure scored as moderate, severe or very severe: BMs too hard, straining to have a BM, feeling like you didn't "finish" a BM, and feeling like you had to pass a BM but could not), in a cohort of non-cancer pain and cancer pain (separately) participants with OIC, by country and overall.

The secondary study objectives are as follows:

1. To estimate the rate of LIR for two subgroups: 1xLIR and 2xLIR. 1xLIR was defined as use of at least one laxative agent ≥ 4 times in the reference period while 2xLIR was defined as the use of at least two laxative agents, each used ≥ 4 times in the reference period; 2. To describe the baseline demographic and clinical characteristics, including prior health status, comorbidities, constipation-related GI symptoms, and concomitant medications of patients with OIC; 3. To describe drug utilization and self-management of OIC; 4. To describe the pre-index and post-index healthcare resource utilization and estimate costs associated with the diagnosis, treatment, and general management of OIC (including laxative use) and events attributed to OIC, including both direct and indirect costs; 5. To describe patient-reported impact of OIC on health-related quality of life, productivity, and pain management; 6. To describe patient-reported treatment satisfaction with laxative use; and 7. To describe physician-reported awareness of OIC and symptoms and understanding of patient-reported impact of OIC.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Patients With Opioid Induced Constipation

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Calgary, Calgary, Alberta, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is receiving a minimum total daily dose of 30 mg of oral morphine, or equianalgesic amount[s] of 1 or more other opioid therapies, for a minimum of 4 weeks for chronic pain or cancer relate pain Presence of OIC in the past 2 weeks
  • (for cancer patients only) Patient has a current diagnosis of cancer that is not currently in remission and has cancer-related pain Internet access and is able and willing to complete a longitudinal web-based survey
  • Patient is able to understand and comply with the requirements of the study, as judged by the investigator (includes ability to read and write and to use

Exclusion criteria

  • Patient is unable or refuses to provide informed consent;
  • Patient does not have access to a computer with internet connectivity, or is unable to use a computer to complete the web-based survey; Based on clinical judgment, patient has a history of chronic constipation (i.e. clinical diagnosis, note in the medical record, or patient history);
  • Patient has a history of (or current) colon cancer (primary or metastatic) (i.e., clinical diagnosis Patient has received an investigational medication to treat constipation or participated in any study involving investigational compound naloxegol within ≤90 days prior to the baseline visit

Treatment and study plan

Primary outcomes

  1. Rate of LIR among the OIC population

    Time frame: 6 months

Secondary outcomes

  1. Rate of inadequate response to first and second-line laxative treatment for OIC (1x LIR and 2x LIR).

    Time frame: 6 months

  2. Baseline demographic and clinical characteristics of patients with OIC (prior health status, comorbidities, GI symptoms, and concomitant medications).

    Time frame: 12months retrospectively

  3. Drug utilization and self-management of OIC at baseline and changes from baseline over the 24-week follow-up period.

    Time frame: 6 months

  4. Healthcare resource utilization profiles pre- and post-baseline

    Time frame: 6 months

  5. Cost of illness related to the diagnosis, treatment, and general management of OIC (including laxative use) and events attributed to OIC, including both direct and indirect costs.

    Time frame: 6 months

  6. Baseline constipation-associated GI symptoms and changes from baseline over the 24-week follow-up period (PAC-SYM and additional symptom questions).

    Time frame: 6 months

  7. Baseline health-related quality of life (PAC-QOL and EQ-5D) and changes from baseline over the 24-week follow-up period (PAC-QOL).

    Time frame: 6 months

  8. Loss of productivity (WPAI-SHP score) at baseline and changes from baseline over the 24-week follow-up period.

    Time frame: 6 months

  9. Persistence on opioid therapy at baseline and changes from baseline over the 24-week follow-up period

    Time frame: 6 months

  10. Treatment satisfaction with laxative use at baseline and changes from baseline over the 24-week follow-up period, for all patients taking laxatives.

    Time frame: 6 months

  11. Physician-reported awareness of OIC and symptoms, and understanding of patient reported impact of OIC at baseline.

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Aug 27, 2013
Registry last updated
Jul 8, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.